Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. - Wikidata - thesis-toulmin - TriplyDB

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.

http://www.wikidata.org/entity/Q33587128

about

Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma.Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma.Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma.CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma

P2860

Q48136793-702DFC90-4DB3-4610-B20F-AF97B4107200 Q55380607-6EA2C115-25E7-41E6-B809-E55B1ED7A18A Q55504502-9CE59F65-B1EE-430D-A18D-1F61066AE9B0 Q56966447-8026810E-8E3C-411D-A524-C347C65A2AE8 Q58773255-5819F29E-9F03-4F63-AD7C-813C0BFDC0FA

P2860

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.

http://www.wikidata.org/entity/Q33587128

description

2017 nî lūn-bûn

@nan

2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.

@ast

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.

@en

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.

@nl

type

label

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.

@ast

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.

@en

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.

@nl

prefLabel

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.

@ast

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.

@en

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.

@nl

P1433

Q33587128-99CB3375-3364-49B9-9DB4-05D61C730E28

P1476

Q33587128-8BEC625A-9DCA-48DC-9A6A-F7325541886A

P2093

Q33587128-05A2ABC5-F2B3-4816-9009-210558A455AA

Q33587128-19BB4E2A-484A-4E02-8F8C-33D5698DF2DC

Q33587128-304218D9-F4F8-44F7-94B6-2BDDDFEB3609

Q33587128-43F030BA-CEAC-4736-9BAF-603103950036

Q33587128-46E503E6-DC84-4F5D-8F9E-F184F945E836

Q33587128-483587C6-CED2-4D13-90FB-121A2F5D366A

Q33587128-492AAD90-7231-4807-AD1B-08D9A665CC66

Q33587128-49718875-86C5-43E9-A589-DECC5D7C42BB

Q33587128-4D0F158F-2614-41DB-9B22-6DDF007FC3ED

Q33587128-57006C8B-4778-4C96-B1CB-5BC80D16645E

P2860

Q33587128-01192D12-CD71-4DC8-B567-FDBD62A5A881

Q33587128-0D3B92FC-05EB-4642-B2F8-4C59320B2759

Q33587128-1E1BC98D-E612-41D2-989D-22D80A74736C

Q33587128-27271887-2ED5-4F8B-B953-D01059D67750

Q33587128-36B502A5-2AC7-4A49-BE9C-43FDBBA1E98E

Q33587128-47AA8FFA-AC98-4926-B768-6CC1183BB68A

Q33587128-4EA54C05-716A-4543-AB65-4BB013D9F9FF

Q33587128-55CFD487-DBAB-4B15-A1C7-252FAEC30EED

Q33587128-5657D184-B9D3-4E27-87CC-268327D7CCEA

Q33587128-5985FDFA-65FD-4C1F-B5EC-7B9AEF753DC2

P2888

Q33587128-E39D0B1E-BA77-4AAA-8293-58F102E66E99

P304

Q33587128-1D7082F8-5269-4ED6-88C2-A5B495CB7BB5

P31

Q33587128-79EAB53F-4844-46AF-8193-5960FEDE6DD9

P356

Q33587128-352284EB-16AB-4089-8132-35948A3D3103

P407

Q33587128-37D70BDE-E48F-4ED8-95A5-4815212FADFC

P478

Q33587128-8A41F8DE-9CAF-4E30-B035-8CD4F1D7BA63

P577

Q33587128-6A07C3FB-B862-4CD5-80A7-2DCFFF22CAAE

P6179

Q33587128-91E6CB2B-B42B-44CF-A8D1-C2E4776A0330

P698

Q33587128-E7192A49-3CA1-49A3-86BE-3177C9291124

P932

Q33587128-B8B8F0AA-883A-42E9-AC2D-A547DABF51F3

P356

P1433

Nature Communications

P1476

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.

@en

P2093

Allison Distler

http://www.w3.org/2001/XMLSchema#string

Ariosto Silva

http://www.w3.org/2001/XMLSchema#string

Bijal Shah

http://www.w3.org/2001/XMLSchema#string

Bin Fang

http://www.w3.org/2001/XMLSchema#string

Chengfeng Bi

http://www.w3.org/2001/XMLSchema#string

Dmitri Rebatchouk

http://www.w3.org/2001/XMLSchema#string

Eduardo Sotomayor

http://www.w3.org/2001/XMLSchema#string

Huijuan Jiang

http://www.w3.org/2001/XMLSchema#string

Jiangchuan Tao

http://www.w3.org/2001/XMLSchema#string

Jianguo Tao

http://www.w3.org/2001/XMLSchema#string

P2860

Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer

The tumor microenvironment shapes hallmarks of mature B-cell malignancies.

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Postibrutinib outcomes in patients with mantle cell lymphoma.

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Large-scale models of signal propagation in human cells derived from discovery phosphoproteomic data.

BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.

Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma

P2888

P304

14920

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCOMMS14920

http://www.w3.org/2001/XMLSchema#string

P407

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084918716

http://www.w3.org/2001/XMLSchema#string

P698

28416797

http://www.w3.org/2001/XMLSchema#string

P932

5399304

http://www.w3.org/2001/XMLSchema#string